title: RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
authors.affiliation: Baltimore, Maryland.
authors.forename: Hugh
authors.initials: H
authors.lastname: Calkins
authors.affiliation: San Francisco, California.
authors.forename: Edward P
authors.initials: EP
authors.lastname: Gerstenfeld
authors.affiliation: London, United Kingdom.
authors.forename: Richard
authors.initials: R
authors.lastname: Schilling
authors.affiliation: Toronto, Canada.
authors.forename: Atul
authors.initials: A
authors.lastname: Verma
authors.affiliation: Hamburg, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Willems
mesh_terms: D001281:Atrial Fibrillation / Q000628:therapy*; D001562:Benzimidazoles / Q000009:adverse effects*; D017115:Catheter Ablation / Q000009:adverse effects*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000209:etiology*; D020521:Stroke / Q000209:etiology*; D013923:Thromboembolism / Q000517:prevention & control*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D001562:Benzimidazoles; D015091:beta-Alanine